GlassScriptPhysician profile
Douglas Naversen
NPI 1568405496
$3,688.46
in general payments reported to CMS, 2019-2025
19 companies · $525 in 2025
The $525 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $109 · 2021: $182 · 2022: $822 · 2023: $844 · 2024: $788 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,990.89 |
| Education | $166.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $993.04 | 2019-2025 | |
| Janssen Biotech, INC. | $821.71 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $568.54 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $231.21 | 2022-2025 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $195.21 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $179.79 | 2023-2024 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $92.77 | 2021 | |
| Genzyme Corporation | $89.03 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $75.80 | 2022-2023 | |
| Pfizer INC. | $74.70 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Arcutis Biotherapeutics, INC. | $69.39 | 2023-2024 | Zoryve |
| Ucb, INC. | $66.48 | 2023-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $50.13 | 2025 | Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.30 | 2023 | Spevigo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $30.39 | 2023 | Ilumya, Blu-U, Odomzo |
| Dermavant Sciences, INC. | $20.71 | 2022 | |
| Incyte Corporation | $16.75 | 2025 | Opzelura |
| Organon LLC | $9.51 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Naversen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.